July 12, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced that David F. Melcher will be non-executive chair of the board of directors, and Claire Pomeroy, MD, MBA, will be a director of the company formed in connection with the previously announced separation of the Diabetes Care business into an independent, publicly traded company, currently referred to as “NewCo.”
The appointments to the NewCo board of directors will be effective upon completion of the spinoff, which is expected to occur in the first half of calendar year 2022. BD says that it expects to announce additional appointments to the NewCo board of directors and executive team prior to that date.
LTG (Ret.) Melcher has experience in leadership positions in the defense community and as a former chief executive officer of a NYSE public company, BD says. He has extensive experience in spinoffs, having served as the inaugural chief executive at Exelis following its spinoff from ITT. Under his leadership, Exelis later spun off its mission systems business as its own NYSE public company. He also has extensive experience and expertise in the areas of domestic and international business, program management, strategy development, finance and information technology. By the time of the spinoff, he will cease to be a director of BD, where he has served as a director since 2017 after previously serving as a director of C. R. Bard, Inc. from 2014 until its acquisition by BD.
Dr. Pomeroy has broad experience in areas of healthcare delivery, health system administration, higher education, medical research and public health. BD says she will bring important perspectives on patient care services, global health and health policy to the NewCo board of directors. By the time of the spinoff, she will cease to be a director of BD, where she has served as a director since 2014.